上海萊士(002252.SZ)孫公司擬接受Biotest的授權在中國地區銷售人血白蛋白注射液
格隆匯10月23日丨上海萊士(002252.SZ)公佈，公司全資孫公司安徽同路醫藥有限公司(“安徽同路”)擬與Biotest PharmaGmbH(“Biotest”)簽署《分銷協議》，安徽同路擬接受Biotest的授權在中國地區銷售其產品，協議金額為700萬歐元，合同金額存在上下25%的浮動，期限自協議簽署之日起至2020年3月31日止。
Biotest為公司控股股東科瑞天誠投資控股有限公司(“科瑞天誠”)和 RAASChina Limited(萊士中國有限公司，“萊士中國”)控制的公司，本次交易構成關聯交易，不構成上市公司《重大資產重組管理辦法》等規定的重大資產重組。
Biotest是一家採用全球製藥和生物治療整體方法、專門研究創新的血液學和免疫學產品的公司。Biotest為母公司Biotest AG產品的市場授權持有人，BiotestAG是一傢俱有70年血液製品製造經驗的全球性全產業鏈血液製品公司，是全球知名的血液製品企業，技術研發能力強，噸漿收入較高，銷售網絡完備，具有較好的發展前景，公司總部位於德國黑森州德賴埃希，現有業務主要為血漿採集與血液製品的生產和銷售，其中血液製品包括人血白蛋白、免疫球蛋白和凝血因子三大類。
協議顯示，Biotest授予安徽同路在經營範圍內獨家銷售產品的權利，聘請合格的醫療領域銷售代表和訓練有素的產品經理。在其分銷許可證允許的範圍內，安徽同路將有權參與招標業務，有權在該經營範圍內營銷和售賣產品，並在合法的情況下有權以患者指定的名義進口產品。授權產品名稱為人血白蛋白注射液。
公司孫公司安徽同路與關聯方發生的交易為主營業務協同發展的需要，安徽同路接受Biotest的授權在中國地區獨家銷售其產品，協議的定價原則和履行方式遵循了公允合規的市場原則，沒有損害公司及中小股東的利益，不會對公司及下屬公司獨立性產生影響，公司及下屬公司的主要業務不會因此類交易而對關聯人形成依賴或者被其控制。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
